This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Endo International plc
Drug Names(s): CPL7075, CT-3
Description: CPL7075 is a non-psychoactive synthetic cannabinoid that appears to suppress inflammatory cytokines, including IL - 1 beta and matrix metalloproteinases (MMPs) through a peroxisome proliferators - activated receptor (PPAR) gamma - mediated mechanism.
Deal Structure: In June 2002, Indevus licensed exclusive, worldwide rights of CT-3 from Atlantic Technology Ventures. The acquisition of CT-3 by Indevus includes an up-front licensing payment, development milestones and royalty payments from Indevus to Atlantic. Indevus is responsible for the clinical development, regulatory activities and commercialization of this compound.
In December 2002, Atlantic Technology Ventures announced that it entered into a merger agreement with Manhattan Pharmaceuticals. Under the terms of the merger agreement, a wholly-owned subsidiary of Atlantic will merger with and into Manhattan, with Manhattan remaining as a wholly-owned subsidiary of Atlantic upon completion of the merger.
In August 2003, Indevus entered into an agreement whereby it was granted exclusive, worldwide rights to certain intellectual property rights. Additionally, in August 2003, Indevus renegotiated its agreement with Manhattan, acquiring all remaining intellectual property rights to the...See full deal structure in Biomedtracker
IP 751 News
Additional information available to subscribers only: